Real-life Use of IV Naxitamab for Children With Relapsed/ Refractory Neuroblastoma

The anti-GD2 antibody Naxitamab requires complicated pain management due to significant adverse effects (AEs). Herein, we report the safety and feasibility of a simplified administration protocol. Between November 2021 and July 2023, 102 Naxitamab infusions were administered at Shaare Zedek Hospital with ketamine as the only analgesic drug during Naxitamab infusion. Pain was controlled in all the cases. Other grade 3-4 AEs, occurred in 10/ 102 infusions (10%), and none of the patients stopped Naxitamab due to infusion-related AEs. Single-agent ketamine is safe and effective for Naxitamab-infusion-related pain. Thus, its use is feasible in multiple clinical settings. Significant infusion-related AEs after the completion of the 3rd treatment cycle are rare.